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Abstract
Objective: Treatment of depression should result in the absence of symptoms, i.e. remission, in
order to restore the functional status of the patient and reduce the risk for relapse. The study
assessed the current remission rates in primary care and determined the influencing factors.
Methods: 10 consecutive depressive patients treated by antidepressants for at least 3 months and
not more than 12 months were screened by each investigator. Remission rates were defined using
the Hamilton-Depression scale 7 items (score of 3 or less) as well as the Carroll self rating scale
(score of 7 or less). In addition, patients completed the Sheehan Disability Scale (SDS). Initial
severity of depression, type of treatment and socio-economic factors were collected.
Results: 292 general practitioners screened a total of 2630 patients. Results indicated low
remission rates: 28.3% according to the clinician and 17.1% according to the patient. Absence of
remission was associated with higher impairment in work, social and family life. The most
frequently reported residual symptoms in nonremitters were general somatic symptoms (92%),
depressed mood (92%), psychic anxiety (91%) and impaired work and activities (89%). No
differences were observed in remission rates between men and women. Remission rates were
significantly lower in patients living alone as compared to those living in couple or family (25.1% vs
30.2%, p=0.03), in patients with lower education (21.3% vs 32.3%, pb0.001), in patients speaking
French as compared to Dutch (24.0% vs 34.0% pb0.001), and unemployed patients compared to
patients having an occupation (17.1% vs 39.0%, pb0.001). Higher initial severity and number of
previous episodes decreased remission rates (pb0.001).ere presented at the 157th annual meeting of the American Psychiatric Association (New York, May
nale Neuropsychopharmacologicum (CINP) Congress (Paris, June 2004), and at the 17th Congress of the
acology (Stockholm, October 2004).
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170 M. Ansseau et al.Conclusion: This study shows low remission rates in depressed patients treated in general
practice. The absence of remission is associated with impairment in work, social and family life.
Special attention should be given to identify patients who do not reach remission.
© 2008 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Depression is a major concern in public health. Indeed,
according to the World Health Organization (WHO), depres-
sion currently represents the second cause of disability in
developed countries (World Health Organization, 2001). Over
the last years, much effort has been devoted to improve the
diagnosis and treatment of the illness. In particular, the
different phases of the treatment have been better defined
as well as the duration of antidepressant therapy. Several
treatment guidelines have been developed by national or
international societies (American Psychiatric Association,
2000; Anderson et al., 2000; Ellis, 2004; Bauer et al., 2002;
Canadian Psychiatric Association, 2001).
The vast majority of depressive patients are seen in
primary care. In epidemiological studies, the prevalence of
major depression in general practice was often higher than
10%, e.g. 11.5% in the US (Spitzer et al., 1994) and 13.9% in
Belgium (Ansseau et al., 2004, 2005).
There is a unanimity among guidelines to consider that the
goal in the treatment of depression is to reach remission, i.e.,
the absence of symptoms. Indeed, the lack of remission
increases the risk for relapse (Pintor et al., 2003, 2004), more
chronic depressive episodes (Judd et al., 2000) and shorter
intervals between episodes (Judd et al., 2000) and continuing
impairment in work, relationship, and overall quality of life
(Keller, 2003; Miller et al., 1998; Murphy et al., 1987). A recent
study in general practice showed that patients non reaching
remission after 3months of treatmentwere nearly 3 timesmore
likely to present a relapse at long-term follow-up (Simon, 2000).
The remission rates obtained in clinical trials of antidepres-
sants were generally found as rather low, between 25 and 35%
(Nierenberg et al., 1999a,b). However, the duration of such
trials is generally too short to reach optimal antidepressant
efficacy. Little is presently known about the rate of remission
among depressive patients treated in natural settings. A recent
study found a remission rate of 27.5% in patients treated with
citalopram for up to 14weeks in “realworld” settings (Trivedi et
al., 2006). Therefore, the objective of the present study was to
assess the actual remission rates of depressive patients treated
in primary care and to determine the influencing factors.
2. Methods
2.1. Selection of investigators and patients
Two hundred and ninety-two general practitioners (GPs) partici-
pated to the study. In order to have representative samples of
patients consulting primary care in Belgium and Luxemburg, the
investigators were geographically distributed over the territory,
with medium to large size practices.
Each investigator was requested to select 10 consecutive
depressive outpatients aged of at least 18 years treated by
antidepressants for at least 3 months and not more than 12 months.The study was performed according to the standards of Good
Clinical Practice. The protocol was approved by the Ethical
Committee of the University of Liège Medical School and all patients
gave their written consent.
2.2. Assessments
First, the investigator collected demographic information concern-
ing his/her patients as well as the method of diagnosis the initial
severity of depression, the number of previous episodes and the
current antidepressant treatment. In addition, the investigator
rated the severity of depression using the shortened 7-item version
of the Hamilton Depression Scale (HAMD-7) (Hamilton, 1960;
McIntyre et al., 2002, 2005). This abbreviated HAMD-7 was recently
demonstrated as equivalent to the HAMD-17 in assessing remission in
patients with a major depressive disorder undergoing drug therapy
(McIntyre et al., 2005). Patients completed the Carroll Depression
Self-Rating Scale (Carroll et al., 1981; Feinberg et al., 1981; Smouse
et al., 1981; Charles et al., 1986) as well as the Sheehan Disability
Scale (Sheehan, 1983; Leon et al., 1997). The Carroll Depression
Scale is a self-rating instrument built to provide scores equivalent to
the 17-item Hamilton Depression Scale; the Sheehan Disability Scale
rates the level of impairment caused by the patient's psychiatric
condition from 0 to 10 on 3 main fields: work, social, and family life.
Remission rates were defined by a score of 3 or less on the 7-item
Hamilton Depression Scale and 7 or less on the Carroll Scale (Frank
et al., 1991; McIntyre et al., 2002, 2005).
2.3. Data analysis
The statistical analysis was both descriptive and inferential. For the
quantitative variables, the descriptive statistics consisted of themean,
median, standard deviation, and 95% confidence intervals on themean;
for the categorical variables, frequencies and percentages. Statistical
tests were performed two-tailed, at the 5% level of significance.
Logistic regression was used to investigate the effect of potential
prognostic factors on the occurrence of remission. First each factor
was compared for patients with and without remission using chi-
square test for the categorical variables, Mann–Whitney test for
ordinal variables and T test for continuous variables.
Subsequently, logistic regression models were applied using a
stepwise approach: all above covariates and two-by-two interactions
were included one by one into the model and those reaching the 5%
level of significance were retained. In that case, odds ratios were
estimated comparing the probability of remission between two levels
of the covariate with an odds ratio N1 corresponding to a higher
probability of remission for the first level compared to the next one.
Since, in case of a significant interaction between two
covariates, odds ratios could no longer be calculated, an additional
model without interaction terms was applied. However, it should be
noted that these odds ratios should be considered as only indicative.
3. Results
3.1. Characteristics of the sample
A total of 2630 patients were included in the study. Their socio-
demographic and clinical characteristics are given in Table 1.
Table 1 Demographical and clinical characteristics of the
sample
n %
Number of patients 2630
Age (mean) 49.7
Gender
Male 734 28
Female 1889 72
Language
French 1962 52
Dutch 1268 48
Family situation
Alone 698 27
Couple/family 1869 71
Group 57 2
Professional status
Without income 285 11
Unemployed/replacement income 437 17
Self-employed 150 6
Worker 331 13
Employee 655 25
Middle management 83 3
Senior executive 50 2
Retired 621 24
Educational level
No degree 117 4
Primary education 286 11
Lower secondary/vocational 818 31
Higher secondary 688 26
Higher non-university 528 20
University 166 6
Initial severity of depression
Mild 565 22
Moderate 1495 58
Severe 529 20
Prior depressive episodes
0 901 36
1 712 29
2 354 14
N2 592 20
Current antidepressant treatment
Tricyclics 71 3
SSRI 1544 61
Citalopram 284 19
Escitalopram 249 17
Fluoxetine 188 12
Paroxetine 422 28
Sertraline 336 22
SNRI 792 31
Others 230 9
Associated anxiolytic 678 26
Associated hypnotic 288 11
171Objective remission of depression in primary careThe initial diagnosis of depressionwasmade by the GP in 85% of
the cases and by a psychiatrist in 10%. Duration of antidepressant
treatment was 6.9 months.
3.2. Remission rates
Remission rates were 28.3% according to the clinicians (HAMD-
7≤3) and 17.1% according to the patients (Carroll rating
scale≤7).
The frequency of residual symptoms, as assessed by the
patients using the Carroll rating scale is provided in Fig. 1.
The most frequently reported residual symptoms were
general somatic symptoms (92%), depressed mood (92%),
psychic anxiety (91%) and impaired work and activities
(89%). All residual symptoms were significantly more
frequent in nonremitted as compared to remitted depressive
patients.
3.3. Correlates of remission
Mean age was identical in remitter and nonremitter depressive
patients. Comparison of socio-economic factors between the
two groups is provided in Table 2. Living alone, unemployment,
lower education and French language were significantly more
frequent in nonremitter depressive patients. Higher initial
severity of the depressive symptomatology decreased the
remission rate with 21.2% for severe level, 27.2% for moderate
level and 41.2% for mild level (pb0.001). In addition, the
presence of previous depressive episodes was associated with
lower remission rate: 39.8% of remission in patients without any
previous episode, 29.2% for patients with one previous episode,
21.0% for two previous episodes and 13.9% for more than two
episodes (pb0.001).
Using logistic regression, two factors were significant in the
model with interaction: number of previous episodes and
initial severity (Table 3): the presence of previous depressive
episodes and higher initial severity of the symptomatology
were associated with lower remission rates. Significant
interactions were found between professional status and
duration of treatment (p=0.004) on the one hand and between
language and education (p=0.0036) on the other hand.
Therefore, since in case of a significant interaction between
two covariates, odds ratios could no longer be calculated, an
additional model without interaction was applied showing the
influence of professional status, duration of treatment,
language and education on remission rates. Concerning
professional status, employees presented remission rates
higher than workers but lower than middle managers and
unemployees. A duration of treatment of 6 months or more was
also a positive factor for remission. Concerning language,
speaking Dutch was indicative of better remission and
concerning education, a higher secondary degree was asso-
ciated with lower remission rate that a lack of degree. However,
it should be noted that these odds ratios should be considered as
only indicative (Table 3).
Regarding treatment duration, a period longer than 6 months
was associated with higher remission rates than a shorter period
(33.2% vs 24.8%, pb0.001). Multivariate analyses showed a
significant improvement in remission rate between 3 and
6 months (pb0.001) but no further improvement for the
remaining of the study period (p=0.928) (Fig. 2).
Figure 1 Comparison of the frequency of residual symptoms, as assessed by the Carroll Depression Scale in remitted and
nonremitted depressive patients.
Table 2 Comparison of remission rates according to socio-
economic factors
Factor % remission p
Gender
Man 30 0.529
Woman 28.5
Living condition
Alone 25.1 0.028
Couple/group 30.2
Professional status
Unemployment 15.9 b0.001
All others 30.6
Education
No/lower education 21.3 b0.001
Higher education 32.3
Language
French 24 b0.001
Dutch 34
172 M. Ansseau et al.On the Sheehan Disability Scale, the absence of remission was
associated with significantly higher impairment in work (5.0 vs
1.6), social life (5.0 vs 1.5) and family life (4.9 vs 1.4) (pb0.001).
4. Discussion
This study shows a very low remission rate for depressive
patients receiving antidepressants for 3 to 12 months in
general practice: 28.3% according to the GP and 17.1%
according to the patient. However, these results confirm
data obtained in clinical trials with only 25 to 35% of
remission rates (Nierenberg et al., 1999a,b). Interestingly,
Trivedi et al. (2006) recently found nearly identical remission
rates (27.5%) among depressive patients treated with
citalopram in primary and psychiatric care settings using
similar definitions. In this study, patients received flexible
doses of citalopram for up to 14 weeks. Like Trivedi's
findings, our study was performed in the “real world” care
settings but differed in several aspects, particularly regard-
ing its cross-sectional design, the longer duration of the
antidepressant treatment (3 to 12 months) and the inclusion
of all types of antidepressants.
Many explanations can be raised for these poor levels
(Nierenberg et al., 2003). Depressed patients could be
satisfied with partial relief of target symptoms such as
sleep and/or appetite disturbances and therefore not
particularly willing to pursue remission as the objective of
treatment. Also, patients may not tolerate or may be
unwilling to accept the side-effects associated with the
optimal dosages of their medications. In addition, general
practitioners may be uncomfortable or unfamiliar with
recommended optimal dosages of antidepressants and may
not feel confident pushing dosages to these levels because of
the risk of side-effects. Patients may also underestimate the
severity of their depression and not pursue treatment.
The lower remission rate according to the evaluation of
the patients as compared to the GPs could depend on
methodological biases. Indeed, the definition of remissionwas based on the 7-item Hamilton Depression Scale for the
GPs and on the Carroll Rating Scale for the patients
themselves. The Carroll Rating Scale was developed as a
self-rating instrument for depression, closely matching the
information content and specific items of the 17-item
Hamilton Depression Scale (Carroll et al., 1981; Feinberg
et al., 1981; Smouse et al., 1981; Nasr et al., 1984).
Comparisons of the two instruments found strong correlation
but some differences: Carroll scores increased more rapidly
than Hamilton scores with increasing severity of depression
(Carroll et al., 1981) and the factor analyses of the two
instruments did not strictly correspond (Smouse et al.,
Table 3 Factors associated with remission (stepwise logistic regression)
Factors p-value Odds ratios [95% Confidence Intervals ]
Model with interaction
Number of previous episodes pb0.001 N2 episodes vs none: 0.300 [0.215–0.418]
2 episodes vs none: 0.441 [0.316 - –0.615]
1 episode vs none: 0.698 [0.548 - –0.888]
Initial severity pb0.001 Severe vs mild: 0.470 [0.337 - –0.655]
Moderate vs mild: 0.600 [0.468 - –0.768]
Model without interaction
Professional status p=0.001 Employee vs:
Retired: 1.266 [0.928–1.728], NS
Senior executive: 1.003 [0.467 - –2.155], NS
Middle management: 0.415 [0.208 - –0.825]
Worker: 1.459 [1.011–2.105]
Self-employed: 1.055 [0.667–1.670], NS
Unemployee: 0.627 [0.430–0.913]
Without any income: 1.323 [0.904 - –1.937], NS
Duration of treatment pb0.001 ≥6 months vs b6 months: 1.731 [1.395–2.104]
Language pb0.001 Dutch vs French: 1.541 [1.257 - –1.888]
Education p=0.003 Higher secondary vs: University: 1.174 [0.737–1.871], NS
Higher non-university: 1.294 [0.962–1.742], NS
Lower secondary/vocational: 0.881 [0.667–1.162], NS
Primary: 0.848 [0.572–1.256], NS
No degree: 0.274 [0.130–0.579]
Stepwise logistic regression: all covariates and two-by-two interactions were included one by one in the model with interaction and those
reaching the 5% level of significance were retained. In that case, odds ratios were estimated comparing the probability of remission
between two levels of the covariate. An odds ratio N1 correspond to a higher probability of remission. Confidence intervals including the
number 1 are non significant (NS). In case of a significant interaction between two covariates, odds ratios could no longer be calculated and
an additional model without interaction terms was applied. However, these odds ratios should be considered as only indicative.
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trend of depressive patients to rate their symptoms as more
severe as compared to observer's ratings. Several studies
support this hypothesis (Tondo et al., 1988), particularly in
nonendogenous depressive patients (Domken et al., 1994;
Ueki et al., 2002, White et al., 1984; Enns et al., 2000). Rush
et al., 1987 suggested that “anxious, atypical, somaticizing
depressives view themselves as more severely depressed
than do clinicians”. In addition, clinicians' assessments were
generally found as more sensitive to change than self-ratings
(Corruble et al., 1999).
The concept and operationalization of remission need to be
discussed. Clinically, remission phase is characterized byFigure 2 Remission rates according to theresolution of the depressive symptoms. In 1991, Frank et al.
proposed operational criteria for remission based on scores of
standardized assessment tools, such as a score of 7 or less on
the 17-item Hamilton Depression Scale or of 8 or less on the
Beck Depression Inventory during at least 2 weeks. More
recently, McIntyre et al. (2002, 2005) validated a shortened
version of the HAM-D comprising 7 items, the Toronto HAM-D 7
scale. A score of 3 or less on the Toronto HAM-D was found to
correlate with a 17-items HAM-D definition of full remission. A
score for defining full remission (10 or less) has also been
validated on the Montgomery and Asberg Depression Rating
Scale (Zimmerman et al., 2004a). A self-report questionnaire,
the clinically useful depression outcome scale, was recentlyduration of antidepressant treatment.
174 M. Ansseau et al.proposed by Zimmerman et al. (2004b). In addition, a survey of
the patients opinion found that the 3 factors that were the
most frequently judged to be very important in determining
remission were the presence of features of positive mental
health such as optimismand self-confidence; a return ton one's
usual, normal self; and a return to usual level of functioning
(Zimmerman et al., 2006).
Theuseof aminimal score ondepression scales such asHAM-
D has been criticised since those instruments contain a large
numberof nonspecific symptoms of depression. In addition, the
cutoff score of 7 on the Hamilton Depression Scale has been
questioned by several clinicians who have suggested that this
cutoff score is too high (Nierenberg et al., 1999a; Judd et al.,
2000). Such a cutoff allows for the presence of residual
symptoms and some patients even qualify for a depressive
disorder diagnosis (Nierenberg et al., 1999b). In a recent study,
Zimmerman et al. (2005) proposed a 17-item HAM cutoff score
of 2 or less. The application of such a cutoff in our sample using
the Carroll scale would have reduced further the number of
remitted depressive patients (4.1%). However, median HAM-D
scores in the general population were found of 2 compared to
20 in patients with major depressive disorder with a cutoff of 7
providing the best differentiation between depressed and
nondepressed persons (Thase, 2002; Thase et al., 2002).
The lack of remission is associated with significantly more
impairment in work, social life and family life, confirming
previous report showing a poor quality of life in nonremitted
depressive patients (Murphy et al., 1987). This finding
stresses the importance of achieving remission.
In our study, several factors appear to play a significant
role in the rate of remission. First, a higher initial severity
and a higher number of previous episodes decrease the
remission rates. Those two factors have long been considered
as associated with poorer prognosis (Hirschfeld et al., 1998,
2002; Swindle et al., 1998; Simon, 2000; Trivedi et al., 2006).
On the socio-economic level, four factors were associated to
lower remission rates: living alone, unemployment, lower
education and speaking French. Living with a spouse or
partner and a higher educational level have already been
demonstrated as predictor of treatment response to anti-
depressants (Joyce and Paykel, 1989; Hirschfeld et al., 1998;
Szadoczky et al., 2004; Swindle et al., 1998; Trivedi et al.,
2006). Similarly, the beneficial role of a professional activity
in the outcome of depression has already been reported
previously (de Graaf et al., 2002; Trivedi et al., 2006). These
findings show that the remission of a depressive episode is
dependent on the socio-economic context. The pharmaco-
logical intervention can be insufficient to modify a patholo-
gical environment.
Our finding of a significant difference between French
and Dutch speaking depressive patients in their remission
rates need some clarifications. Belgium is composed of 2
main communities, speaking Dutch in the north (the
Flanders) and French in the south (Wallonia); Brussels, the
capital of the country is mainly composed of French-speaking
citizens. The economic situation of the Dutch-speaking
region is currently much better than the French-speaking
areas; for instance, the percentage of unemployment is
16.7% in Wallonia, 20.3% in Brussels and 7.5% in Flanders
(Belgian Government, 2005). However, there are data
possibly pointing to socio-cultural rather than to socio-
economic factors and more precisely to the attitude towardsuffering. Northern countries exhibit a more stoicist attitude
toward adversity than their southern counterparts. This is
indirectly demonstrated by the much more frequent
recourse to anxiolytic drugs in French speaking countries.
For example, according to Pelissolo et al. (1996), 25–30% of
the French general population are occasional or regular users
of anxiolytic and hypnotic drugs with between 5 and 7%
chronic users, corresponding to 2 to 3 times superior to most
industrialized countries. In the survey by Ohayon and Lader
(2002), France has the highest proportion of anxiolytic users
(9.0%) followed by Italy (5.8%); the rate is only 0.7% in
Germany and 0.6% in the U.K.
In contrast, gender does not appear to play a significant
role in remission rates, confirming previous reports (Zlotnick
et al., 1996; Szadoczky et al., 2004). A recent report,
however, found that female patients presented higher
remission rates than male subjects (Trivedi et al., 2006).
Several limitations in the design of this study should be
acknowledged and discussed. First, no systematic diagnostic
procedure was imposed. Patients were included if they were
initially diagnosed as depressives and treated by antidepres-
sants. Despite its limitations, this method corresponds better
to the treatment procedure applied in general practice
where due to time limitations systematic diagnostic proce-
dures are very rarely used. Second, the study uses a cross-
sectional design which does not enable us to follow the
evolution of the treated patients over time. In addition, the
sample could have been somewhat biased since only those
patients reconsulting their GP between 3 and 12 months of
antidepressant therapy were included. Therefore, patients
who did not reconsult their practitioner due to either rapid
or complete recovery or on the opposite lack of any
improvement and even worsening leading to referral to a
specialist or hospitalisation are not evaluated.
It would have been of real interest to perform similar
study among patients seen by psychiatrists to evaluate if
their therapeutic results are better than those of GPs.
Several reports seem to indicate that psychiatrists could
obtain higher remission rates than primary care physicians
(Gruen et al., 2004). A recent study, however, found
comparable remission rates in primary and psychiatric care
for depressive patients treated with citalopram (26.6% vs
28.0%) (Trivedi et al., 2006).
In total, the findings of this study show that much progress
has still to be made for improving the treatment of
depression in primary care. A recent review shows that
strategy which revealed effective in improving patient
outcome generally are those with complex interventions
that incorporated clinician education and a greater degree of
integration, between primary and secondary care (Gilbody
et al., 2003). This is clearly a challenge for the future.
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